Effects of an antitumoural rhodium complex on thioacetamide-induced liver tumor in rats. Changes in the activities of ornithine decarboxylase, tyrosine aminotransferase and of enzymes involved in fatty acid and glycerolipid synthesis.
Rats were injected daily for 8 weeks with 50 mg of thioacetamide per kg to produce liver tumours. Some of these rats were given three doses of 50 mg of an antitumoural Rh(III) complex/kg at 14, 9 and 5 days before the end of the thioacetamide treatment. Thioacetamide decreased the rate of weight gain of the rats and the Rh(III) complex partly restored it. The activities of ATP citrate lyase, acetyl-CoA carboxylase and fatty acid synthetase in the livers were decreased by thioacetamide treatment and the Rh(III) complex partly reversed this effect. By contrast the activity of malic enzyme was increased by both thioacetamide and the Rh(III) complex and this effect probably relates to NADPH production for detoxification rather than for lipogenesis. Treatment with thioacetamide increased the rate of synthesis of di- and triacylglycerols from glycerol phosphate by liver homogenates, the activity of phosphatidate phosphohydrolase and the incorporation of [3H]glycerol into liver triacylglycerol in vivo. The Rh(III) complex did not produce a significant reversal of these effects of thioacetamide on glycerolipid synthesis. The total uptake of intraportally injected [3H]glycerol by the livers of thioacetamide treated rats was decreased and this was associated with a lowered activity of glycerol kinase. Thioacetamide increased the activity of hepatic ornithine decarboxylase by about 40-fold, but the Rh(III) complex did not reverse this effect. However, the decrease in tyrosine aminotransferase activity that was produced by thioacetamide was partly reversed by the Rh(III) complex. These results are discussed in relation to the tumour-promoting effects of thioacetamide and the antitumoural action of the Rh(III) complex.
D001275:ATP Citrate (pro-S)-Lyase / Q000378:metabolism; D000081:Acetamides; D000103:Acetyl-CoA Carboxylase / Q000378:metabolism; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001835:Body Weight / Q000187:drug effects; D004075:Diglycerides / Q000096:biosynthesis*; D064429:Fatty Acid Synthases / Q000378:metabolism; D005227:Fatty Acids / Q000096:biosynthesis*; D005989:Glycerides / Q000096:biosynthesis*; D005991:Glycerol Kinase / Q000378:metabolism; D005992:Glycerol-3-Phosphate O-Acyltransferase / Q000378:metabolism; D007527:Isoenzymes; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D008113:Liver Neoplasms / Q000139:chemically induced* / Q000201:enzymology; D008291:Malate Dehydrogenase / Q000378:metabolism; D008297:Male; D009929:Organ Size / Q000187:drug effects; D009955:Ornithine Decarboxylase / Q000378:metabolism*; D010711:Phosphatidate Phosphatase / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains; D012238:Rhodium / Q000494:pharmacology*; D013853:Thioacetamide; D014280:Triglycerides / Q000096:biosynthesis*; D014444:Tyrosine Transaminase / Q000378:metabolism*
D000081:Acetamides; D000970:Antineoplastic Agents; D004075:Diglycerides; D005227:Fatty Acids; D005989:Glycerides; D007527:Isoenzymes; D014280:Triglycerides; D013853:Thioacetamide; D012238:Rhodium; D007770:L-Lactate Dehydrogenase; D008291:Malate Dehydrogenase; D005992:Glycerol-3-Phosphate O-Acyltransferase; D064429:Fatty Acid Synthases; D001275:ATP Citrate (pro-S)-Lyase; D014444:Tyrosine Transaminase; D005991:Glycerol Kinase; D010711:Phosphatidate Phosphatase; D009955:Ornithine Decarboxylase; D000103:Acetyl-CoA Carboxylase